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Abstract
Background: Previous studies have examined the spectrum of diseases identified with a kidney
biopsy and the complications of the procedure. However, few studies have examined the utility of
the test to clarify the diagnosis and guide treatment of pediatric patients. This retrospective, single-
center chart review was performed to test the hypothesis that at least 80% of native kidney
biopsies provide clinically valuable information that rationally guides diagnosis and patient
management.
Methods: 200 biopsies performed between January 1, 2000 and June 30, 2008 were reviewed. A
scheme composed of six categories was devised to classify the utility of each kidney biopsy.
Results: 196 complete case files were available for review. Twenty-four (12.2%) biopsies did not
shed light on the diagnosis and were unhelpful in patient management – 21 biopsies (10.7%) were
non-diagnostic and 3 (1.5%) failed to yield enough tissue for examination. The number of unhelpful
biopsies did not cluster in any specific disease entity.
Conclusion: Our findings provide guidance to nephrologists about the total risk of a kidney
biopsy, including uninformative results, when seeking informed consent for the procedure. The
results suggest an appropriate balance has been reached which maximizes the use of kidney
biopsies while minimizing the risk of this invasive procedure (word count: 202).
Background
A kidney biopsy is an important diagnostic procedure in
nephrology and can aid in determining the appropriate
diagnosis, treatment, and prognosis for specific patients.
Based upon physical examination, urinalysis and blood
tests, physicians attempt to make a clinical diagnosis
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which is used to guide treatment. This is not always feasi-
ble using non-invasive tools, and in such cases a kidney
biopsy may need to be performed to confirm or determine
the diagnosis, severity, and urgency of therapy.
A kidney biopsy may not always provide information that
is needed or pertinent to the clinical scenario. Sometimes
an adequate tissue sample of the kidneys cannot be
obtained or the information provided from the biopsy
fails to shed any light on the patients' symptoms or clini-
cal data. Due to the invasiveness of the procedure, it is
important, when recommending a biopsy for an individ-
ual patient, to bear in mind not only the risks of the pro-
cedure itself but the distinct possibility that it might prove
unhelpful in the patient's management.
There are a number of recent studies that have detailed the
array of diagnoses obtained from kidney biopsies in
adults [1-8] and children [9-13] with renal disease. Other
reports have assessed the clinical impact that a biopsy may
have, but they focused primarily on the risk factors and
resulting complications of performing renal biopsies [4].
In this study, we defined a novel system that enabled us to
ascertain the usefulness of a particular biopsy by analyz-
ing predictions of the diagnosis pre-biopsy and the physi-
cian's treatment decision post biopsy. Using this scheme,
we tested the hypothesis that at least 80% of native kidney
biopsies provided clinically valuable information that
rationally guided the formulation of the patient's progno-
sis and treatment.
Methods
Patients
A database of biopsy procedures was obtained from the
Department of Pathology that contained information on
all native kidney biopsies completed at Schneider Chil-
dren's Hospital between January 1, 2000 and June 31,
2008. The database included the patient's name, date of
biopsy, date of birth, and final diagnosis.
The medical records of patients were retrieved from active
clinical files or from off-site storage. The following data
were extracted from each available chart: age, gender,
blood pressure, dipstick urinalysis results, height (cm),
serum creatinine, estimated glomerular filtration rate
(GFRe), and urine protein/creatinine ratio in an early
morning specimen at the last evaluation prior to the
biopsy. In addition, the reason for biopsy, physician's pre-
dicted diagnosis, the biopsy-confirmed diagnosis, and
treatment outcome were recorded. The predicted diagno-
sis was based on the correspondence from the nephrolo-
gist who performed the biopsy to the patient's primary
physician or was based on the clinical diagnosis recorded
on the biopsy report at the time of submission of the tis-
sue sample.
Classification of diagnostic outcomes of the biopsy: A six-
point scheme was designed to determine whether the
biopsy served as a useful tool in establishing treatment. If
the physician conclusively predicted a particular diagnosis
which the biopsy confirmed, the patient was categorized
as type 1. A type 2 categorization denoted a biopsy that
confirmed one of multiple possible diagnoses. A type 3
categorization accounted for an incorrect pre-biopsy pre-
diction but in which the biopsy finding was conclusive
and sufficient to determine appropriate treatment. If the
biopsy was used to determine the severity of an estab-
lished disease, category 4 was assigned to that patient.
Failures were identified as either content based or techni-
cal and were separated accordingly. Thus, patients in
whom the biopsy was insufficient on its own to define
prognosis and treatment were categorized as type 5. Tech-
nical failures, namely an inability to obtain tissue, were
categorized as type 6.
Each case was independently reviewed by one of the four
primary authors (AP, JR, BS, FT). Clinical and biopsy
reports were recorded and categorized according to the
scheme outlined above. Agreement between all pairs of
primary reviewers was reached in over 85% of all cases.
When there was a discrepancy between the primary
reviewers, an independent observer (RF), who did not
perform the biopsy, reviewed the case. This reviewer also
checked randomly selected charts for accuracy and agreed
with the primary reviewers in all cases. A nurse was chosen
to adjudicate conflicts among the primary reviewers and
to confirm accuracy of the chart reviews because this per-
son would be less likely to be biased in interpreting the
utility of the kidney biopsy procedures. The nephrologist
who did the kidney biopsy did not participate in the cate-
gorization of the informational outcome of the procedure
to avoid potential bias.
Statistical Methods
Data are reported as mean ± SD. Differences in proportion
were assessed by the chi square or Fisher exact test as
appropriate. Differences were considered statistically sig-
nificant if the P value was <0.05. All information was
gathered on a pre-approved form.
Data were de-identified and coded by study number in
accordance with the Health Insurance Portability and
Accountability Act guidelines (HIPAA). This chart review
was approved by the Institutional Review Board of North
Shore-LIJ Health System.
Results
A total of 200 biopsies were identified in the pathology
database. All charts were retrieved. 4 charts were excluded
because the biopsy was done at a different center and the
diagnostic assessment and its impact on management byBMC Nephrology 2009, 10:11 http://www.biomedcentral.com/1471-2369/10/11
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the attending physician could not be directly assessed.
Thus, this report is based on the outcomes of 196 kidney
biopsies.
The number of biopsies per year is illustrated in Figure 1
which demonstrates a fairly steady rate of performance of
this procedure. The vast majority, 183 out of 196 (93%),
of the procedures were performed in the outpatient set-
ting. The hospitalized patients represented the cohort in
which a kidney biopsy was done to assess acute renal dys-
function. The clinical characteristics of the patients are
summarized in Table 1. Of note, 77 (59%) of the patients
had UP/C >1 and 30 (15%) had GFRe <90 mL/min/1.73
m2.
Eleven of the patients who had biopsies underwent repeat
biopsies. Nine patients had a second biopsy, one had
three, and another underwent four procedures. In the last
case, of the four biopsies performed, one of the biopsies
was a technical failure. In two of these patients, the first
biopsies were normal or non-diagnostic and subsequent
biopsies showed FSGS and MPGN, respectively. In two
other patients, neither the original nor follow up biopsies
resulted in a definitive diagnosis. In the remaining 6
patients, the repeat kidney biopsy was done to assess
response to treatment, 4 in patients with SLE and 2 in
patients with MPGN.
Fifty-eight (29%) patients were classified as type 1, 28
(15%) were type 2, 27 (14%) were type 3, 59 (30%) were
type 4 (Figure 2). Of the unsuccessful biopsies, 21
(10.7%) of the biopsies were inconclusive and further
testing was required to confirm a diagnosis (type 5). In 3
of these cases, treatment was based upon the clinical find-
ings rather than the histopathological diagnosis reported
after the biopsy. In the remaining 18 cases, 5 patients were
started on non-immunosuppressive, renoprotective treat-
ment, 8 were followed without initiation of any disease-
specific therapy, and 5 were lost to follow-up or trans-
ferred to internal medicine nephrology services for further
care. Therefore, these biopsies were considered unhelpful.
Finally, 3 (1.5%) biopsies failed to yield adequate tissue
samples (type 6).
The diagnostic utility of the kidney biopsies based on the
pre-biopsy diagnosis is summarized in Table 2. The per-
centage of diagnostically failed biopsies ranged from 0 to
33%. However, focusing on diagnostic entities that con-
tained ≥ 10 patients, there were no significant differences
in the rate of this problem for any specific clinical entity.
Discussion
In this review, useful biopsies were defined as those that
definitively established the diagnosis and which provided
solid guidance to the attending nephrologist on how to
This graph illustrates the annual number of biopsies during the study period, 01/2000 – 06/2008 Figure 1
This graph illustrates the annual number of biopsies during the study period, 01/2000 – 06/2008.
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treat the patient. Of the 196 kidney biopsies done
between 2000 and 2008 for which complete data were
available, we determined that 172 (88%) were useful as
defined above. In particular, of the 113 kidney biopsies
that were done for diagnostic purposes (types 1, 2, 3) 85%
were helpful, and all of the procedures done to assess
severity were also deemed helpful. From a clinical per-
spective, categories 1–4 were all considered useful and
could have been combined into one group. We divided
them into four distinct subcategories to better characterize
how nephrologists utilize the information content of a
kidney biopsy in a productive manner.
In most circumstances, a renal biopsy is a semi-elective
procedure, and technical failures can occur when the pro-
cedure fails to obtain adequate tissue. Of all the biopsies
analyzed in this study, only 3 were technical failures. The
fact that renal biopsies were not useful in 12.2% of cases
needs to be considered in assessing the benefit of perform-
ing biopsies. In those cases, further testing is needed after
the biopsy, and treatment has to be guided by clinical fac-
tors rather than the histopathological findings. In our
study, we found the overall yield of uninformative biop-
sies was 12.2%, which is below the 20% threshold that we
defined as an acceptable rate. This constitutes an accepta-
ble risk/benefit ratio. Despite the potential risks involved,
families can be reassured that a renal biopsy will be help-
ful in the great majority of patients who must undergo the
procedure.
In judging this study, it is worth noting that there has been
general uniformity in practice and staffing over the study
period. One physician (HT) has been one of the primary
nephrologists over the past 20 years and active through-
out the 8-year study period and one pathologist (EV)
interpreted all the biopsies from 2000 to 2007. It is rea-
sonable to conclude that there was consistency in the use
of kidney biopsies to predict, diagnose, and treat patients
suspected of having kidney disease. The number of biop-
sies performed per year (Figure 1) showed no consistent
trend, upward or downward, reinforcing the uniformity of
the practice. We chose to focus on the years 2000–2008 in
order to shed light on the utility of the kidney biopsy dur-
ing a period that reflects current medical practice.
Although it would have been optimal to have the interpre-
tation of all biopsy reports reviewed by the independent
observer, the four primary authors agreed in over 80% of
cases. Moreover, the physician who performed the kidney
biopsy was never involved in the retrospective assessment
of diagnostic utility of the procedure. Despite the focused
duration of the study and the single center nature of the
review, a sufficient number of patients were identified that
enabled conclusions to be drawn from our experience.
It is important to acknowledge that the study cannot
definitively assess the utility of kidney biopsies performed
to determine severity (type 4) in SLE patients. We
assumed the results to be useful, excluding those in which
a technical failure occurred, because the biopsies identi-
fied the WHO class of the disease in all cases and presum-
ably guided treatment by the rheumatologists. This
reflects the approach to patient management at Schneider
Children's Hospital in which the care of children with SLE
nephritis is delivered primarily by the rheumatologists
unless the patients have specific issues such as hyperten-
sion, edema, or progress to end stage kidney disease. The
utility of the biopsy may vary in those centers where neph-
rologists directly supervise the full care of patients with
SLE. In addition, this study was limited to native kidney
biopsies and did not address the value of transplant biop-
sies. Finally, we have not commented on complications of
the procedure because we have reviewed our experience in
a previous publication which confirms the overall safety
of kidney biopsies performed using ultrasound localiza-
tion [14].
Based upon clinical experience and perennial difficulties
distinguishing between FSGS and MCNS clinically, we
anticipated that kidney biopsies performed on these
patients would have the highest non-diagnostic rate.
Table 2 indicates, however, that the rate of unhelpful
biopsies performed on FSGS and MCNS patients was not
significantly different compared to biopsies performed for
other conditions, and the maximum non-diagnostic rates
for any of the major diseases was 10–20%. The entities
with higher failure rates involved small numbers of
patients, which precludes meaningful conclusions.
It is likely that nephrologists will always have to grapple
with the fact that there will be a percentage of biopsies
Table 1: Kidney Biopsy Patient Clinical Features
GFRe 131.9 ± 65
Urine protein/creatinine 3.2 ± 4.6
Systolic blood pressure 117 ± 17
Diastolic blood pressure 70 ± 11
Age (yr) 12 ± 5
≤ 10 years 37%
Proteinuria* 77.36%
Hematuria** 86%
Data are provided as mean ± SD.
*Proteinuria indicates ≥ 1+ by dipstick testing; **Hematuria indicates 
≥ small by dipstick testing.BMC Nephrology 2009, 10:11 http://www.biomedcentral.com/1471-2369/10/11
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that fail to yield a diagnosis. Too small a percentage sug-
gests too stringent requirements for performing a kidney
biopsy. Conversely, a high percentage suggests that kidney
biopsies are being performed for inadequate indications.
The issue of an acceptable value will vary depending upon
the urgency of the patient's clinical situation, the spec-
trum of clinical outcomes that might occur, and the avail-
ability of treatments that can materially alter the outcome
of an anticipated disease entity. For example, pediatric
surgeons recognize that not every child with abdominal
pain who undergoes a laparotomy should have appendi-
citis because they realize it is better to occasionally find a
normal abdomen rather than manage a ruptured appen-
dix. Interestingly, a recent report in the surgical literature
suggests that an acceptable negative appendectomy rate is
10–20%, in the range of our rate of negative kidney biop-
sies [15]. In view of the spectrum of kidney problems that
mandated a biopsy, it may be difficult to define a single
acceptable rate of non-diagnostic biopsies, and we offer
our findings as a basis for future considerations on this
issue.
In summary, we present our findings about the diagnostic
value of a kidney biopsy in a varied group of pediatric
patients. The overall rate of 12% seems to strike an appro-
priate balance between maximizing the application and
minimizing the risk of this invasive procedure. Our find-
ings may need to be reassessed as clinical information
regarding specific disease changes and technical innova-
This graph illustrates the diagnostic categories for the 196 biopsies with complete information that were reviewed Figure 2
Category 1: Predicted diagnosis confirmed    
Category 2: One of several predicted diagnoses confirmed  
Category 3: Unexpected but treatable diagnosis made  
Category 4: Assessment of disease severity  Category 5: Non-diagnostic  
Category 6: Technical failure  
This graph illustrates the diagnostic categories for the 196 biopsies with complete information that were 
reviewed. Note that the values for percentage in the pie chart have been rounded off to whole numbers. 1, a biopsy that 
revealed the specific diagnosis predicted by the physician; 2, a biopsy that confirmed one of multiple possible diagnoses; 3, a 
biopsy that revealed disease that was different than the pre-biopsy prediction but which was conclusive and sufficient to deter-
mine appropriate treatment; 4, a biopsy done to determine the severity of an established disease; 5, a biopsy that was insuffi-
cient on its own to define prognosis and treatment; 6, a biopsy that was a technical failure with inability to obtain tissue.
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tions are introduced in the performance of kidney biop-
sies and handling renal tissue specimens.
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Table 2: Failure by Prebiopsy Diagnosis
Diagnoses Failure
Diagnosis N % N %
Systemic Lupus Erythematosus 66 34% 8 12%
Focal segmental glomerulosclerosis 59 30% 9 15%
IgA Nephropathy 32 16% 2 6%
Minimal Change Nephrotic Syndrome 17 9% 2 13%
Membranoproliferative Glomerulonephritis 16 8% 2 13%
Henoch Schoenlein Pupura Nephritis 12 6% 2 17%
Membranous Nephropathy 11 6% 2 18%
Acute Interstitial Nephritis 10 5% 2 20%
Hereditary nephritis (Alport/FTBMN) 10 5% 0 0%
Glomerulonephritis 7 4% 1 24%
Post Infectious Glomerulonephritis 7 4% 1 14%
Wegener granulomatosis 3 2% 1 33%
Miscellaneous 11 6% 1 9%
Abbreviation: FTMBN: familial thin basement membrane nephropathy
the number of pre-biopsy diagnoses exceeds the number of biopsies 
performed because each potential diagnosis that was considered as a 
clinical possibility before the procedure is listed in the Table.